Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

Sree Harsha Tirumani, Ann S. Lacasce, Heather A. Jacene

Research output: Contribution to journalArticlepeer-review

Abstract

The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

Original languageEnglish (US)
Pages (from-to)207-225
Number of pages19
JournalPET Clinics
Volume10
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Keywords

  • Diffuse large B-cell lymphoma
  • FDG-PET/CT
  • Hodgkin lymphoma
  • Interim PET/CT
  • Lymphoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma'. Together they form a unique fingerprint.

Cite this